Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents

Angela R. Smith, Tanya L. Repka, Brenda J. Weigel

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Nausea and vomiting are common side effects of chemotherapy in adult and pediatric patients. Even with standard antiemetic therapy, a significant number of patients continue to experience acute and delayed symptoms. When used in combination with standard antiemetic therapy, a new class of antiemetics, the neurokinin-1 (NK-1) receptor antagonists, have been shown to improve both acute and delayed nausea and vomiting in adults. In this report, we describe the NK-1 receptor antagonist aprepitant in two adolescent patients receiving highly emetogenic chemotherapy who had experienced refractory nausea and vomiting with previous chemotherapy courses. The addition of aprepitant to the antiemetic regimen in the patients resulted in significant subjective improvement in nausea and vomiting as well as quality of life. These results in our adolescent patients are promising, but there is a need for well-designed studies to determine the efficacy, dosing, and safety of aprepitant in children of all ages.

Original languageEnglish (US)
Pages (from-to)857-860
Number of pages4
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Oct 2005


  • Antiemetics
  • Aprepitant
  • Chemotherapy-induced nausea and vomiting (CINV)
  • Neurokinin-1 receptor antagonists
  • Pediatrics


Dive into the research topics of 'Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents'. Together they form a unique fingerprint.

Cite this